{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:36:48Z","timestamp":1767865008572,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007500","name":"Bloomberg Philanthropies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007500","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.josat.2024.209351","type":"journal-article","created":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T01:20:52Z","timestamp":1710638452000},"page":"209351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership"],"prefix":"10.1016","volume":"162","author":[{"given":"Kathryn N.","family":"Burke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noa","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isha K.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachini","family":"Bandara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth A.","family":"Feder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2024.209351_bb0005","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"10.1016\/j.josat.2024.209351_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108784","article-title":"Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder?","volume":"225","author":"Dunphy","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.josat.2024.209351_bb0015","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13012-022-01239-y","article-title":"Stepped implementation-to-target: A study protocol of an adaptive trial to expand access to addiction medications","volume":"17","author":"Ford","year":"2022","journal-title":"Implementation Science"},{"issue":"9","key":"10.1016\/j.josat.2024.209351_bb0020","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.2105\/AJPH.89.9.1322","article-title":"Evaluating the public health impact of health promotion interventions: The RE-AIM framework","volume":"89","author":"Glasgow","year":"1999","journal-title":"American Journal of Public Health"},{"issue":"2","key":"10.1016\/j.josat.2024.209351_bb0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20843","article-title":"Differences in availability and use of medications for opioid use disorder in residential treatment settings in the United States","volume":"3","author":"Huhn","year":"2020","journal-title":"JAMA Network Open"},{"issue":"4","key":"10.1016\/j.josat.2024.209351_bb0030","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11414-020-09706-4","article-title":"Organizational facilitators and barriers to medication for opioid use disorder capacity expansion and use","volume":"47","author":"Jacobson","year":"2020","journal-title":"The Journal of Behavioral Health Services & Research"},{"issue":"8","key":"10.1016\/j.josat.2024.209351_bb0035","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment","volume":"105","author":"Jones","year":"2015","journal-title":"American Journal of Public Health"},{"issue":"8","key":"10.1016\/j.josat.2024.209351_bb0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.27488","article-title":"Use of medication for opioid use disorder among adults with past-year opioid use disorder in the U.S., 2021","volume":"6","author":"Jones","year":"2023","journal-title":"JAMA Network Open"},{"issue":"4","key":"10.1016\/j.josat.2024.209351_bb0045","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.evalprogplan.2011.02.004","article-title":"Barriers to the implementation of medication-assisted treatment for substance use disorders: The importance of funding policies and medical infrastructure","volume":"34","author":"Knudsen","year":"2011","journal-title":"Evaluation and Program Planning"},{"issue":"9","key":"10.1016\/j.josat.2024.209351_bb0050","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1111\/add.14991","article-title":"Opioid agonist treatment and fatal overdose risk in a state-wide U.S. population receiving opioid use disorder services","volume":"115","author":"Krawczyk","year":"2020","journal-title":"Addiction"},{"key":"10.1016\/j.josat.2024.209351_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019","volume":"110","author":"Krawczyk","year":"2022","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.josat.2024.209351_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108645","article-title":"Users of retail medications for opioid use disorders faced high out-of-pocket prescription spending in 2011-2017","volume":"132","author":"McClellan","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.josat.2024.209351_bb0065","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1377\/hlthaff.2018.05162","article-title":"Medication treatment for opioid use disorders in substance use treatment facilities","volume":"38","author":"Mojtabai","year":"2019","journal-title":"Health Affairs"},{"issue":"2","key":"10.1016\/j.josat.2024.209351_bb0070","first-page":"1000140","article-title":"Buprenorphine prescribing availability in a sample of Ohio specialty treatment organizations","volume":"4","author":"Molfenter","year":"2015","journal-title":"Journal of Addictive Behaviors, Therapy & Rehabilitation"},{"key":"10.1016\/j.josat.2024.209351_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108540","article-title":"Potential barriers to filling buprenorphine and naltrexone prescriptions among a retrospective cohort of individuals with opioid use disorder","volume":"133","author":"Morgan","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"6","key":"10.1016\/j.josat.2024.209351_bb0080","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.addbeh.2011.01.032","article-title":"Using medication-assisted treatment for substance use disorders: Evidence of barriers and facilitators of implementation","volume":"36","author":"Roman","year":"2011","journal-title":"Addictive Behaviors"},{"issue":"8","key":"10.1016\/j.josat.2024.209351_bb0085","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/jamapediatrics.2017.1269","article-title":"Closing the medication-assisted treatment gap for youth with opioid use disorder","volume":"171","author":"Saloner","year":"2017","journal-title":"JAMA Pediatrics"},{"key":"10.1016\/j.josat.2024.209351_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108424","article-title":"Association between availability of medications for opioid use disorder in specialty treatment and use of medications among patients: A state-level trends analysis","volume":"132","author":"Solomon","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209351_bb0095","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"British Medical Journal"},{"key":"10.1016\/j.josat.2024.209351_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108900","article-title":"Not in my treatment center: Leadership\u2019s perception of barriers to MOUD adoption","volume":"144","author":"Stewart","year":"2023","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209351_bb0105","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)"},{"key":"10.1016\/j.josat.2024.209351_bb0110","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)"},{"issue":"2","key":"10.1016\/j.josat.2024.209351_bb0115","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924000638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924000638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T06:25:15Z","timestamp":1717914315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875924000638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":23,"alternative-id":["S2949875924000638"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2024.209351","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2024.209351","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"209351"}}